Nature 508, 215–221 (2014); doi:10.1038/nature13181

In this Article, the structure of compound TH650 (4) in Fig. 4a was drawn incorrectly; the correct structure is shown as Fig. 1 to this Corrigendum. Preparative, spectroscopic and biological data associated with this compound are as reported in the Article, and the error does not influence any of the reported data or interpretations. In addition, two of the short hairpin RNA (shRNA) sequences in the Methods section were incorrect and should read as follows: MTH1 shRNA #2 5′-CGAGTTCTCCTGGGCATGAAA-3′; and MTH1 shRNA #3 5′-CGACGACAGCTACTGGTTT-3′.

Figure 1
figure 1

This is the correct chemical structure of TH650 (4) from Fig. 4a.

Full size image

We have since found that the reported pENTR4 vector expressing OGG1 and MUTYH carried a frameshift mutation, and as a result the overexpressed mRNA does not translate into proteins. This was not determined in the original Article, as only mRNA was measured. To evaluate whether the OGG1 and MUTYH proteins affect sensitivity to the MTH1 inhibitor TH588, we generated a pENTR1A vector and expressed OGG1 and MUTYH in U2OS cells (see Supplementary Fig. 1 to this Corrigendum). We find that the overexpression of OGG1 and MUTYH does not influence sensitivity to TH588 (Supplementary Fig. 1 of this Corrigendum), in line with what was originally reported. Hence, the interpretation of the results is as presented in the original Article.

Finally, we would like to add the following sentence to the end of the current ‘Competing financial interests’ statement: “The patent covers compound matters and is fully owned by a not-for-profit public foundation, the Helleday Foundation, that supports medical research. There is no reward scheme to inventors.” The original Article has not been corrected.